Abstract
OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P <0.001). The area under the receiver operating chacteristic curve was greater (P <0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values 7.00 (P <0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 940-942 |
| Number of pages | 3 |
| Journal | Diabetes Care |
| Volume | 38 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Cite this
The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. / Sosenko, Jay M; Skyler, Jay S; Beam, Craig A.; Boulware, David; Mahon, Jeffrey L.; Krischer, Jeffrey P.; Greenbaum, Carla J.; Rafkin, Lisa; Matheson, Della; Herold, Kevan C.; Palmer, Jerry P.
In: Diabetes Care, Vol. 38, No. 5, 01.05.2015, p. 940-942.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months
AU - Sosenko, Jay M
AU - Skyler, Jay S
AU - Beam, Craig A.
AU - Boulware, David
AU - Mahon, Jeffrey L.
AU - Krischer, Jeffrey P.
AU - Greenbaum, Carla J.
AU - Rafkin, Lisa
AU - Matheson, Della
AU - Herold, Kevan C.
AU - Palmer, Jerry P.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P <0.001). The area under the receiver operating chacteristic curve was greater (P <0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values 7.00 (P <0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.
AB - OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P <0.001). The area under the receiver operating chacteristic curve was greater (P <0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values 7.00 (P <0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.
UR - http://www.scopus.com/inward/record.url?scp=84958651977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958651977&partnerID=8YFLogxK
U2 - 10.2337/dc14-2787
DO - 10.2337/dc14-2787
M3 - Article
C2 - 25758770
AN - SCOPUS:84958651977
VL - 38
SP - 940
EP - 942
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 5
ER -